ConvEyXO strives to unleash the full therapeutic potential of exosomes. The company was founded in 2019 by a team of seasoned cell therapy experts committed to making exosome-based therapies more widely available and affordable.
To strengthen its intellectual property portfolio of proprietary methods, technologies, and physical assets, ConvEyXO has set up several collaborations, joint ventures, acquisitions, and in-licensing agreements. This has resulted in a unique platform that combines breakthrough manufacturing (Exo-Harvest) and loading (XomeXBio) technologies. Together, they will enable the cost-effective large-scale production of exosomes capable of delivering bioactive compounds in a targeted way.
An ecosystem of strategic partners with complementary expertise has evolved. These partnerships typically tackle a specific challenge: